Molecular Pharmacology Fast Forward. Published on September 21, 2004 as DOI: 10.1124/mol.104.003350
Molecular Pharmacology Fast Forward. Published on September 21, 2004 as doi:10.1124/mol.104.003350
This article has not been copyedited and formatted. The final version may differ from this version.

MOL3350

The human sulfotransferase *SULT1A1* gene is regulated in a synergistic manner by Sp1 and GA Binding Protein.

Nadine Hempel, Hongbing Wang, Edward L. LeCluyse, Michael E. McManus and Masahiko Negishi

Department of Physiology and Pharmacology, School of Biomedical Sciences, University of Queensland, Brisbane, Queensland 4072, Australia (NH and MEM)

Division of Drug Delivery and Disposition, School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina 27599, USA (HW and ELL)

Pharmacogenetics Section, Laboratory of Reproductive and Developmental Toxicology, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina 27709, USA (NH and MN)

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 19, 2024

Copyright 2004 by the American Society for Pharmacology and Experimental Therapeutics.

Molecular Pharmacology Fast Forward. Published on September 21, 2004 as DOI: 10.1124/mol.104.003350
This article has not been copyedited and formatted. The final version may differ from this version.

Running Title:

Regulation of the human sulfotransferase *SULT1A1* gene

To whom correspondence should be addressed:

Dr. Michael E. McManus, Executive Dean, Faculty of Biological & Chemical Sciences, University of Queensland, Brisbane Qld 4072, Australia, Tel.: 61-7-3365-1609, Fax: 61-7-3365-1613, E-mail address: m.mcmanus@uq.edu.au

Number of Text Pages: 44

Number of Figures: 10

Number of References: 40

Number of words

Abstract: 248

Introduction: 747

Discussion: 1475

Abbreviations:

CAR, constitutive androstane receptor; Citco, 6-(4-chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime; cytochrome P450, CYP; EBS, Ets binding sequence; EMSA, electrophoretic mobility shift assay; GABP, GA binding protein; PAPS, 3'-phosphoadenosine 5'-phosphosulfate; 5'RACE, 5'rapid amplification of cDNA ends; Rb-IgG, normal rabbit immunoglobulin G; SULT, sulfotransferase; UGT, UDP-glucuronosyltransferases; 5'UTR, 5'untranslated region.

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 19, 2024

Molecular Pharmacology Fast Forward. Published on September 21, 2004 as DOI: 10.1124/mol.104.003350
This article has not been copyedited and formatted. The final version may differ from this version.

Abstract:

Human sulfotransferase SULT1A1 is an important phase II xenobiotic metabolizing enzyme, which is highly expressed in the liver and mediates the sulfonation of drugs, carcinogens and steroids. Until this study the transcriptional regulation of the SULT1A subfamily had been largely unexplored. Preliminary experiments in primary human hepatocytes showed that SULT1A mRNA levels were not changed in response to nuclear receptor activators, such as dexamethasone and 3-methylcolanthrene, unlike other metabolizing enzymes. Using HepG2 cells, the high activity of the TATA-less *SULT1A1* promoter was shown to be dependent on the presence of Sp1 and Ets transcription factor binding sites (EBS), located within -112 nucleotides from the transcriptional start site. The homologous promoter of the closely related SULT1A3 catecholamine sulfotransferase, which is expressed at negligible levels in the adult liver, displayed 70% less activity than *SULT1A1*. This was shown to be due to a two basepair difference in the EBS. The Ets transcription factor GA Binding Protein (GABP) was shown to bind the *SULT1A1* EBS and could transactivate the *SULT1A1* promoter in *Drosophila* S2 cells. Co-transfection of Sp1 could synergistically enhance GABP-mediated activation 10-fold. Although Sp1 and GABP alone could induce *SULT1A3* promoter activity, the lack of the EBS on this promoter prevented a synergistic interaction between the two factors. This study reports the first insight into the transcriptional regulation of the *SULT1A1* gene and identifies a crucial difference in regulation of the closely related *SULT1A3* gene, which accounts for the two enzymes' differential expression patterns observed in the adult liver.

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 19, 2024

Molecular Pharmacology Fast Forward. Published on September 21, 2004 as DOI: 10.1124/mol.104.003350
This article has not been copyedited and formatted. The final version may differ from this version.

Introduction:

The human SULT1A subfamily of cytosolic sulfotransferases (SULT) belongs to a super gene family of enzymes that catalyze the transfer of a sulfonate group from 3'-phosphoadenosine 5'-phosphosulfate (PAPS) to a wide variety of xenobiotic and endogenous compounds such as drugs, carcinogens, steroids and neurotransmitters (Falany, 1997). Unlike other species the human SULT1A subfamily contains more than one member (SULT1A1, SULT1A2 & SULT1A3), which share >92% identity at the amino acid level (Wilborn et al., 1993; Zhu et al., 1993a; Zhu et al., 1993b; Ozawa et al., 1995). The three *SULT1A* genes are found within close proximity to each other on chromosome 16 (16p12.1-p11.2) suggesting their recent evolution from a gene duplication event (Dooley et al., 1994; Bernier et al., 1996; Dooley and Huang, 1996; Raftogianis et al., 1996). SULT1A1 plays a significant role in the sulfo-conjugation of xenobiotics, such as *p*-nitrophenol, N-hydroxy-heterocyclic and -aromatic amines, and endogenous compounds such as di-iodothyronine and estrogens (Falany, 1997; Brix et al., 1999; Richard et al., 2001). SULT1A1 is found in large abundance in the liver and in a wide variety of tissues including the intestine, lung, kidney, endometrium, placenta, skin and platelets (Butler et al., 1983; Zhu et al., 1993b; Windmill et al., 1998; Rubin et al., 1999; Dooley et al., 2000; Stanley et al., 2001). In contrast, SULT1A3, which is the major sulfotransferase involved in catecholamine sulfonation, is barely expressed in the adult liver but is present in significant amounts in the intestine, lung, platelets and the fetal liver (Butler et al., 1983; Windmill et al., 1998; Richard et al., 2001). Although considerable information is available on the structure-function relationships of these two enzymes their transcriptional regulation has not been explored in great detail.

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 19, 2024

Molecular Pharmacology Fast Forward. Published on September 21, 2004 as DOI: 10.1124/mol.104.003350
This article has not been copyedited and formatted. The final version may differ from this version.

Most studies investigating the gene regulation of cytosolic SULTs have focused on the rodent isoforms and their response to nuclear receptor activators. Rat and mouse SULT1A1 and SULT2 isoforms and human SULT2A1 enzyme levels were shown to be induced by glucocorticoids (Runge-Morris et al., 1998; Wu et al., 2001; Duanmu et al., 2002). In addition, the constitutive androstane receptor (CAR) activator phenobarbital has been shown to cause a decrease in rat SULT1A1 and 2A1 and a 4-fold increase in rat SULT2A2 mRNA levels (Runge-Morris, 1998). A recent study demonstrated that dexamethasone increased SULT1A1 expression in the rat liver, but no such effect was observed in cultures of human primary hepatocytes (Duanmu et al., 2001; Duanmu et al., 2002). Although the rodent and human SULT1A1 enzymes share 77% amino acid identity, their promoter regions are quite distinct in sequence. These differences, together with the fact that humans possess three SULT1A members compared to a solitary isoform in rodents, make it difficult to extrapolate the mechanisms regulating human SULT1A expression from animal *SULT* gene regulation studies.

When the human SULT1A cDNA species were isolated variable 5' untranslated regions (5'UTR) were observed, which were suggestive of either the use of alternate transcriptional start sites or alternate post-transcriptional splicing (Wilborn et al., 1993; Zhu et al., 1993a; Zhu et al., 1993b; Bernier et al., 1994a; Wood et al., 1994; Aksoy and Weinshilboum, 1995; Raftogianis et al., 1996). It was noted that these alternate transcripts may be tissue specific; however, the true endogenous ramifications remain unclear, as all transcripts contain the same coding sequence. Bernier *et al.* (1996) showed that the human *SULT1A1* gene sequence upstream of the more distal 5'UTR had higher promoter activity than the sequence immediately upstream of the ATG start codon. The distal 5'UTR appears to be part of the most common SULT1A1 mRNA

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 19, 2024

Molecular Pharmacology Fast Forward. Published on September 21, 2004 as DOI: 10.1124/mol.104.003350
This article has not been copyedited and formatted. The final version may differ from this version.

species identified by investigators and was the transcript first isolated by our laboratory from a liver cDNA library (Zhu et al., 1993a).

The objective of this study was to unravel the mechanisms of gene regulation of the human SULT1A subfamily, with particular emphasis on the *SULT1A1* promoter. In this study we provide the first explanation as to how this gene is regulated at the transcriptional level. The region immediately upstream of the distal 5'UTR on the *SULT1A1* gene harbors a highly active promoter, lacking canonical TATA box elements but containing G/C rich regions, which are responsible for the action of Sp1 on the promoter. Furthermore, the high activity of the human *SULT1A1* promoter is driven by a synergistic action between the Ets transcription factor GA Binding Protein (GABP) and Sp1, and the lower promoter activity observed for *SULT1A3* is due to a 2 basepair difference in an Ets transcription factor binding sequence (EBS) on this gene that prevents this synergistic effect.

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 19, 2024

Molecular Pharmacology Fast Forward. Published on September 21, 2004 as DOI: 10.1124/mol.104.003350
This article has not been copyedited and formatted. The final version may differ from this version.

Materials and Methods:

Materials. Dexamethasone, rifampicin, 3-methylcolanthrene, phenobarbital, DMSO and other common reagents were purchased from Sigma-Aldrich (St. Louis, MO) or local suppliers, unless otherwise stated. 6-(4-chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime (Citco) was kindly provided by Dr Steven Kliewer (University of Texas Southwestern Medical Center, Dallas, TX; Maglich et al., 2003). Cell culture media, fetal bovine serum (FBS) and trypsin/EDTA were obtained from Invitrogen (Carlsbad, CA). Oligonucleotides were purchased from Sigma Genosys (The Woodlands, TX) or Invitrogen Custom Primers. TaqMan Real-time probes were synthesised by Applied Biosystems (Foster City, CA)

Treatment of Primary human Hepatocytes and Real-Time RT-PCR. Liver tissues for primary human hepatocytes cultures were obtained with the patient's consent and the approval of the University of North Carolina Hospitals Ethics Committee. All tissues were isolated by qualified medical staff from patients undergoing liver resection from metastatic tumors. From these only hepatocytes exhibiting normal morphology were isolated and cultured in 6 well plates as previously described (Wang et al., 2003). Cells were treated for 16-18 hours with nuclear receptor activators dexamethasone (1μM), rifampicin (10μM), 3-methylcolanthrene (3-MC, 5μM), phenobarbital (1mM), Citco (1μM) or vehicle DMSO. RNA was isolated from cells with TRIzol Reagent (Invitrogen) and reverse transcription of 2μg RNA was carried out using the SuperScript Reverse transcription kit for RT-PCR (Invitrogen). The RT-PCR was carried out on an ABI Prism^{TM} 7700 sequence detector (PE Applied Biosystems), with 2x TaqMan Universal

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 19, 2024

Molecular Pharmacology Fast Forward. Published on September 21, 2004 as DOI: 10.1124/mol.104.003350
This article has not been copyedited and formatted. The final version may differ from this version.

Mastermix (PE Applied Biosystems), 1µl of reverse-transcribed RNA, 20x β-actin internal standard control mix, containing the Vic fluorescent label (PE Applied Biosystems), 50ng of each sense and antisense primer and 5pmol of probe. The reaction was carried out after an initial hold at 50^{o}C for 2 min and a denaturing step at 95^{o}C for 10 min, followed by 40 cycles of denaturing at 95^{o}C for 15 sec and combined annealing and extension at 60^{o}C for 1 min. The following probe and primer sets, designed on Primer Express Software (PE Applied Biosystems), were used: SULT1A1 sense primer (s) 5'GCAACGCAAAGGATGTGGCA3', antisense primer (a/s) 5'TCCGTAGGACACTTCTCCGA3' (Dooley et al., 2000), probe 6FAM-ACATGGCCAAGGTGCACCCTGAGCC-TAMARA; SULT1A3 s 5'GGAACCCTCAGGGCTGGAG3', a/s 5'CGTCCTTTGGGTTTCGGG3', probe 6FAM-GCCCCCACGGCTCATCAAGTCACACC-TAMARA; cytochrome P450 2B6 (CYP2B6) s 5'AAGCGGATTTGTCTTGGTGAA'3, a/s 5'TGGAGGATGGTGGTGAAGAAG3', probe 6FAM-CATCGCCCGTGCGGAATTGTTC-TAMRA; CYP3A4 s 5'TCAATAACAGTCTTTCCATTCCTCAT3', a/s 5'CTTCGAGGCGACTTTCTTTCA3', probe 6FAM-TTTCCAAGAGAAGTTAC-MGBNFQ; UDP-glucuronosyltransferases 1A1 (UGT1A1; Sugatani et al., 2001) s 5'GGCCCATCATGCCCAATAT3', a/s 5'TTCAAATTCCTGGGATAGTGGATT3', probe 6FAM-TTTTTGTTGGTGGAATCAACTGCCTTCAC-TAMRA).

SULT1A Immunoblotting. Recombinant human SULT1A1 and SULT1A3, cloned in pET28(a)+ (Promega, Madison, WI), were bacterially expressed in BL21(DE3) cells as previously described (Brix et al., 1999) and the histidine tag cleaved by overnight

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 19, 2024

Molecular Pharmacology Fast Forward. Published on September 21, 2004 as DOI: 10.1124/mol.104.003350
This article has not been copyedited and formatted. The final version may differ from this version.

incubation with 2units of thrombin. Total bacterial cytosol (0.1µg) and 75µg of primary human hepatocyte cytosol were electrophoresed on a 14% acrylamide gel and subjected to western blotting. The goat anti-humanSULT1A1 antibody is able to cross react with all three human SULT1A proteins (Brix et al., 1999). After secondary incubation with Anti-Goat Horse Radish Peroxidase conjugated antibody (Santa Cruz, Santa Cruz, CA), proteins were visualized by ECL exposure (Amersham, Piscataway, NJ) and autoradiography.

5'Rapid Amplification of cDNA Ends (5'RACE). SULT1A1 5'RACE was carried out using human liver Marathon Ready cDNA (0.2ng; Clontech, Palo Alto, CA), with *SULT1A1* gene specific antisense outer primer (OP; 1µM; 5'GGGAATCCCTGGGGCTTTGAACTC3'), located within the second coding exon, the cDNA adapter primer AP1 (1µM), 200µM dNTP mix and the Advantage 2 Polymerase mix and buffer (Clontech), using the following PCR cycling conditions: Initial denaturing at 94^{o}C for 30 seconds; 5 cycles of denaturing at 94^{o}C for 5 sec and a combined annealing and extension time at 72^{o}C for 4 min; followed by 30 cycles of denaturing at 94^{o}C for 5 sec and annealing/extension at 70^{o}C for 4 min. This was followed by a second amplification of 1/50 of the PCR product with the SULT1A1 inner primer (IP; 5'CACTTCTCCAGGTCACCACCCTGGTA3'), located just upstream of the OP site. A control PCR was carried out with OP and a control sense primer (CP; 5'CGCCCGCCACTGGAGTACGTG3') located in the first coding exon. 5'RACE PCR products were electrophoresed, purified, cloned into the pCR2.1 vector (Invitrogen) and sequenced using BigDye Terminator Ready Reaction Mix (Stratagene, La Jolla, CA).

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 19, 2024

Molecular Pharmacology Fast Forward. Published on September 21, 2004 as DOI: 10.1124/mol.104.003350
This article has not been copyedited and formatted. The final version may differ from this version.

Promoter Constructs and Expression Plasmids. The *SULT1A* promoter regions were amplified using the Long *Taq* Plus DNA polymerase system (Stratagene) from human genomic DNA. The heterologous primer set (s 5'GAGCTGTGAGGAAGTTCAGGTC3'; a/s 5'GATCAGCTCCATGTTCCTGCATC3') was used to amplify approximately 4kb of sequences upstream of the start codon of all three human *SULT1A* genes. The PCR was performed with the following cycling conditions: an initial 2min denaturing step at 94^{o}C was followed by 30 cycles of denaturing at 92^{o}C for 30 sec, annealing of primers at 66^{o}C for 1min, and extension at 72^{o}C for 5 min, followed by an additional 5 cycles, with increased extension time to 15 min. The PCR products were cloned into the pCR2.1 vector (Invitrogen) and sequenced. Restriction enzymes *Nsi*I, *Cla*I and *Kpn*I (New England BioLabs, Beverly, MA) were used to differentiate the three sequences by specifically cutting only *SULT1A1*, *SULT1A2* and *SULT1A3* sequences, respectively. Promoter deletion constructs were created by PCR, using *Pfu Turbo* DNA polymerase (Stratagene) and the above *SULT1A* promoter constructs as template. The constructs were cloned into the pGL3Basic luciferase reporter vector (Promega, Madison, WI). The QuickChange Site Directed Mutagenesis Kit (Stratagene) was used to incorporate site mutations as indicated in Figure 4a.

Human GABPα (Accession No.: NM_002040), GABPβ1 (NM_005254), Ets-1 (NM_005238), Ets-2 (NM_005239), Elf-1 (NM_172373), Elk-1 (NM_005229) and Tel-1 (NM_001987) cDNAs were isolated from HepG2 cDNA by PCR using TaKaRa *LATaq* polymerase (Panvera, Madison, WI). Primers were based on the sequence available from the GenBank/NCBI database and the PCR carried out at an initial denaturing step

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 19, 2024

Molecular Pharmacology Fast Forward. Published on September 21, 2004 as DOI: 10.1124/mol.104.003350
This article has not been copyedited and formatted. The final version may differ from this version.

at 94^{o}C for 1 min, followed by 40 cycles of denaturing at 94^{o}C for 30 sec, annealing of primers at 49^{o}C for 30 sec and extension at 72^{o}C for 3 min, with a 15 sec increase in extension time, per cycle. The PCR was concluded by a final extension at 72^{o}C for 10 min and the purified PCR products cloned into the TOPO TA pCDNA3.1 vector (Invitrogen). Ets factors were subcloned into the pAC5.1 *Drosophila* expression vector (Invitrogen). Sp1 and Sp3 in pPac were kindly provided by Dr. Guntram Suske, Philipps University, Marburg, Germany.

Cell Culture, Transfection and Luciferase Assay. Human hepatocarcinoma cell lines, HepG2 and Hep3B, were obtained from ATCC and grown in minimum essential medium containing 10% FBS. Transfection of promoter constructs was carried out at ~70-80% confluency using the CellPhect Transfection Kit (Amersham, Piscataway, NJ). The *SULT1A* promoter luciferase reporter constructs or the empty pGL3-Basic vector (0.1μg/well) were transfected together with control *Renilla* luciferase reporter vector pRL-SV40 (0.05μg/well) in 24-well plates. Media was changed 24 hours post-transfection and luciferase activities of the lysed cells measured using the Dual Luciferase Kit (Promega), after an additional 24 hours in culture. Each result represents the mean and standard deviation of three transfections and assays were repeated 2-3 times to confirm reproducibility. Primary human hepatocytes were seeded into 24 well bio-coated plates and grown in Williams' Medium E (Sigma), supplemented with 1% insulin/transferrin/sodium selenite supplement (Sigma) and 0.1μM dexamethasone. Cells were transfected with *SULT1A* promoter constructs (0.25μg/well) and the pRLSV40 control (0.025μg/well) after 48 hours in culture, using Effectene Transfection

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 19, 2024

Molecular Pharmacology Fast Forward. Published on September 21, 2004 as DOI: 10.1124/mol.104.003350
This article has not been copyedited and formatted. The final version may differ from this version.

Reagent (Qiagen, Valencia, CA). Media was changed the following day and luciferase activities measured as stated above, after an additional 24 hours in culture. *Drosophila melanogaster* S2 cells were cultured in Schneider's *Drosophila* medium (Invitrogen) supplemented with 10% FBS at 25^{o}C. Cells were transferred to 12 well dishes at a density of 0.5x10^{6} cells per well and transfections carried out the following day using the Calcium Phosphate method, as per protocol of the *Drosophila* Expression System kit (Invitrogen). Each well was transfected with 1μg of *SULT1A* promoter reporter construct and where indicated with 1-5μg of the following: Sp1, Sp3, GABPα, GABPβ, Ets1, Ets2, Elf, Elk or the empty pAC5.1 or pPac-UBX vectors. Media was changed after 18 hours post transfection. After 24 hours in culture, cells were lysed and luciferase activity measured (Promega). Luciferase activity was normalized against protein concentration of the cleared lysate (BioRad Protein Assay, Hercules, CA).

Electrophoretic Mobility Shift Assay (EMSA). Nuclear extracts from cell lines were isolated as described by Dignam *et al*. (1983). Recombinant Ets transcription factors were expressed using the *in vitro* rabbit TNT reticulocyte lysate transcription/translation system (Promega). Complimentary oligonucleotide probes with 5' linkers GATC (*SULT1A1* wild type [wt], 5'CCTTCCTTCCGGAAGCAA3'; and EBS mutants [m], see Figure 4a) were annealed and end-labeled with [α-^{32}P]dATP (Amersham). The radio-labeled probe (~15,000cpm) was incubated with 3-5μg nuclear extract or 3-6 μl of rabbit reticulocyte lysate expressed protein, in 20mM Tris-HCl (pH7.5) buffer, containing 1μg poly(dIdC), 0.1mM DTT, 50mM NaCl, 10% glycerol for 45 minutes at room temperature. The protein:DNA complexes were electrophoresed on a 5% polyacrylamide gel in 7mM

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 19, 2024

Molecular Pharmacology Fast Forward. Published on September 21, 2004 as DOI: 10.1124/mol.104.003350
This article has not been copyedited and formatted. The final version may differ from this version.

Tris-HCl (pH7.5), 3mM sodium acetate and 1mM EDTA, and visualized by autoradiography. In supershift experiments nuclear extract was pre-incubated with 2μg of antibody for 1 hour on ice. Anti- mouse GABPα and β polyclonal antibodies were previously prepared (Yokomori et al., 1995) and normal rabbit Immunoglobulin G (Rb-IgG), Ets-2 and Elf-1 antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). The anti-mouse GABP antibodies were shown to cross-react with the human recombinant GABP proteins (not shown).

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 19, 2024

Molecular Pharmacology Fast Forward. Published on September 21, 2004 as DOI: 10.1124/mol.104.003350
This article has not been copyedited and formatted. The final version may differ from this version.

Results:

Human SULT1A1 and 1A3 mRNA is not induced by activators of the glucocorticoid receptor, CAR, pregnane X receptor (PXR) or aryl hydrocarbon receptor (AhR) in primary human hepatocytes. Figures 1a-e show the result for Real-time RT-PCR of human primary hepatocytes from one of two donors treated with various nuclear receptor activators. Phenobarbital, which elicits the well-known induction pathway for the CYP2B family and the phase II enzymes UGT1A1 via CAR (Pascussi et al., 2003; Sugatani et al., 2001), did not influence SULT1A1 mRNA levels in these cells. Even the newly described human CAR activator Citco (Maglich et al., 2003) failed to change SULT1A1 mRNA levels. As previously reported, the glucocorticoid receptor agonist dexamethasone had no influence on SULT1A1 mRNA levels (Duanmu et al., 2002), contrary to the increases in CYP3A4 levels observed, a known target gene of this receptor (El-Sankary et al., 2000). Similarly, the PXR activator rifampicin did not alter the SULT1A1 levels but had a significant effect on inducing CYP3A4 and UGT1A1 mRNA levels. Treatment of the AhR ligand 3-methylcolanthrene caused a 5-fold induction of UGT1A1 levels, but again had no effect on SULT1A1 mRNA. Treatments of hepatocytes from other donors resulted in similar induction profiles for the CYP and UGT1A1 mRNAs, but again did not produce significant changes in SULT1A1 levels. Additionally, no changes in SULT1A3 levels were observed with the treatments. Generally the mRNA levels of SULT1A3 in primary human hepatocytes were lower than those of SULT1A1 (Figure 1f) and SULT1A3 protein could not be detected in hepatocyte cytosol using immunoblotting, unlike the high abundance of SULT1A1 protein observed (Figure 1g).

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 19, 2024

Molecular Pharmacology Fast Forward. Published on September 21, 2004 as DOI: 10.1124/mol.104.003350
This article has not been copyedited and formatted. The final version may differ from this version.

***SULT1A1* promoter properties.** Early cloning studies of human SULT1A1 cDNAs demonstrated the presence of different mRNA species, which varied only in their 5'UTRs. Figure 2a shows a schematic of the 5'region of the *SULT1A1* gene, indicating the positions of the three 5'UTRs reported in the literature; a 5'UTR immediately upstream of the ATG start codon (Zhu et al., 1993b), a proximal 5'UTR (A; (Raftogianis et al., 1996) and a distal 5'UTR (B ; (Wilborn et al., 1993; Zhu et al., 1993a). To identify the transcriptional start site of the *SULT1A1* gene in the liver, 5'RACE was carried out which resulted in the amplification of a single 63bp product, located 1071bp upstream from the ATG start codon of *SULT1A1* (results not shown). This represents the most common cDNA species previously described, containing the distal 5'UTR B; (Wilborn et al., 1993; Zhu et al., 1993a). The furthest 5' transcriptional start site identified in this study was denoted as bp +1, with other 5'RACE products displaying start sites at 3, 8 and 10 bp downstream of this site. This distal 5'UTR was also the major sequence amplified from HepG2 cDNA when RT-PCR with primers positioned in the alternate 5'UTRs was performed (results not shown). This hepatocarcinoma cell line was used to initially characterize the *SULT1A1* promoter.

The distal 5'UTR was further confirmed to contain the start site of transcription when promoter activities of the sequences in front of all reported 5'UTRs were assessed in HepG2 cells. The 1371 bp sequence 5' of the start codon (Exon I) exhibited only 2.7-fold higher luciferase activity than the empty vector alone (Figure 2b). The sequence immediately upstream of the proximal 5'UTR A did not produce a significant luciferase signal, which reflects our RT-PCR data, where an mRNA species containing this 5'UTR could not be amplified. In contrast, the sequence located upstream of the transcriptional start site identified in 5'RACE (5'UTR B) displayed considerable basal activity, with the -

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 19, 2024

Molecular Pharmacology Fast Forward. Published on September 21, 2004 as DOI: 10.1124/mol.104.003350
This article has not been copyedited and formatted. The final version may differ from this version.

1217/+65 construct having 140-fold higher activity than the empty pGL3Basic vector alone (Figure 2b).

To characterize this highly active *SULT1A1* promoter we analyzed the properties of several deletion constructs in HepG2 cells. These displayed steadily increasing luciferase activity when deleted, with the -112/+65 construct exhibiting highest activity; a 230-fold increase from the empty vector (Figure 2c). Further deletion of an additional 44 bp (-68/+65) resulted in a 90% decrease in activity, indicating the presence of a crucial regulatory element in this region. The *SULT1A1* promoter constructs displayed similar activity patterns when transfected into primary human hepatocytes and Hep3B cells and the deletion to -68/+65 resulted in an equally dramatic decrease in promoter activity suggesting a common mechanism of regulation in these cell types (Figure 2d).

Identification of a crucial ETS binding site (EBS) by comparison to the less active *SULT1A3* promoter. Three different 5'untranslated regions were previously shown to exist in SULT1A3 cDNA species isolated from a variety of cDNA libraries (Figure 3a; (Zhu et al., 1993a; Bernier et al., 1994a; Aksoy and Weinshilboum, 1995). SULT1A3 5'RACE results from liver cDNA were inconclusive, most likely due to the limited transcription of this gene in this tissue. However, cloning of the *SULT1A3* gene sequences flanking these 5'UTRs into the pGL3Basic vector and assessing their ability to act as promoters in driving luciferase transcription revealed that only the sequence flanking 5'UTR A, which is homologous to the distal 5'UTR B of *SULT1A1*, was a functional promoter in HepG2 cells (Figure 3b).

These two *SULT1A* promoters share >60% sequence identity in the 3kb upstream of their transcriptional start sites. A notable 3-fold difference in activities between the

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 19, 2024

Molecular Pharmacology Fast Forward. Published on September 21, 2004 as DOI: 10.1124/mol.104.003350
This article has not been copyedited and formatted. The final version may differ from this version.

SULT1A1 and *SULT1A3* promoters was observed, which was used as an effective tool to delineate the molecular mechanisms differentially controlling the transcriptional regulation of the two *SULT1A* genes in this liver derived cell line (Figure 4a). The *SULT1A3* -125/+43 promoter construct displayed 70% less activity than the homologous *SULT1A1* -112/+65 construct in HepG2 cells. Both *SULT1A* genes appear to have TATA-less promoters, which are rich in GC areas. Analysis of the *SULT1A1* sequence using the Patch, Match and Transfac database programs (http://www.gene-regulation.com), identified a high homology match to the Ets transcription factor binding site (EBS) core sequence GGAA, located on the sense strand at bases -92 to -89 (EBS1) and as a tandem repeat immediately upstream of this on the antisense strand [Figure 4b; EBS2&3]. Flanking the EBS repeats on either side are two Sp1 sites. The *SULT1A3* sequence lacks 6bp downstream of the EBS repeats (Figure 4b). Additionally, *SULT1A3* has a two nucleotide mismatch in the EBS1 motif, but has EBS2, EBS3 and the Sp1 sites conserved. To assess whether the difference in promoter activities between *SULT1A1* and *SULT1A3* is due to a difference in sequence between bases -112 and -68, a chimeric construct was created that introduced the *SULT1A3* region into the *SULT1A1* promoter (alt1A3). This caused a 70% decrease in *SULT1A1* promoter activity and resulted in luciferase levels similar to those observed for wild type *SULT1A3* (wt; Figure 4c). Interestingly this same reduction in activity could also be achieved by changing two bases in the EBS1 motif of *SULT1A1* to those found in *SULT1A3*, thereby disrupting the Ets binding core motif GGAA (1A1EBS1m; Figure 4c). The importance of this motif was further highlighted by introducing the consensus GGAA EBS1 into *SULT1A3*, which significantly increased promoter activity and effectively converted it to that observed for the wild type *SULT1A1* promoter (Figure 4c).

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 19, 2024

Molecular Pharmacology Fast Forward. Published on September 21, 2004 as DOI: 10.1124/mol.104.003350
This article has not been copyedited and formatted. The final version may differ from this version.

The roles of the adjacent EBS2 and EBS3 on the antisense strand were assessed by a series of mutations in the *SULT1A1* -112/+65 construct and by analysis of promoter activity in HepG2 cells (Figure 5a). Mutations disrupting either EBS2 or EBS3 resulted in a 50% reduction in promoter activity. Mutations of all three EBS GGAA motifs resulted in a decrease to 10% of the original *SULT1A1* -112/+65 wild type promoter activity, and resembled the activity observed with the -68/+65 deletion construct, suggesting the need for the presence of all three EBS sites for maximal promoter activity.

Identification of Ets factors binding the *SULT1A1* EBS motifs. EMSA of HepG2 nuclear extract with the *SULT1A1* -102/-85 ^{32}P-labeled oligonucleotide probe, incorporating the EBS motifs, revealed the formation of several specific protein:DNA complexes (A-C, Figure 5b). These were competed out by molar excess of unlabeled probe, but not by a probe containing mutations in the three EBS. Three bands were observed at position A with HepG2 and Hep3B nuclear extract. The band at position B was enhanced in the EMSA with Hep3B nuclear extract. Additionally there was a lower migrating doublet at C. A non-specific (*n/s*) signal was also observed. To assess the importance of the individual EBS motifs, ^{32}P-radiolabeled *SULT1A1* -102/-85 probes containing mutations in these sites were incubated with HepG2 nuclear extract (Figure 5c). It was observed that the bands at position A were only present if EBS3 was intact [Figure 5c, -102/-85, EBS1m, EBS2m]. Band B and C lost intensity with a mutation in EBS(1), which also represents the *SULT1A3* wild type sequence, but appeared to increase in intensity when mutations were made in EBS3, suggesting that the protein:DNA complexes at position B and C require the presence of EBS1 and that a

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 19, 2024

Molecular Pharmacology Fast Forward. Published on September 21, 2004 as DOI: 10.1124/mol.104.003350
This article has not been copyedited and formatted. The final version may differ from this version.

shift of binding can occur when one of the GGAA triplicate motifs is disrupted. All binding was abolished when nuclear extract was incubated with the probe containing mutations in all three EBS motifs.

Several Ets transcription factors could be isolated from HepG2 cDNA, which were potential candidates of the endogenous Ets factors controlling *SULT1A1* gene regulation in these cells. Indeed, using an antibody supershift EMSA it was possible to show the presence of two Ets factors in the protein:DNA complexes formed by the *SULT1A1* EBS probe and hepatocarcinoma cell nuclear extract. Figure 6a shows the supershift EMSA performed with preincubation of HepG2 nuclear extract with antibodies against the widely expressed Ets factors Ets2, Elf1, GABPα and β. No supershift was observed with the antibody against Ets2, which is also able to cross-react with Ets1. The protein:DNA complex at position B could be identified to contain the Ets transcription factor Elf1. The presence of Elf1 in band B was further highlighted when the EBS3 mutant probe was incubated with nuclear extract and Elf1 antibody. This probe enhanced binding of band B, which clearly disappears with addition of this antibody. Anti-mouse GABPβ was able to supershift all bands at position A (Figure 6a). The antibody against mouse GABPα also supershifted these, except the lowest band, which may represent a variant of human GABPα that is not readily detectable by the antibody raised against the mouse isoform, yet is able to form a heterodimer with GABPβ and is hence supershifted with the GABPβ antibody. GAPBα requires its non-DNA-binding heterodimeric partner GABPβ for its transcriptional activity (LaMarco et al., 1991). It has been shown that GABPα and β can form both heterodimers and tetramers and that these have the same effect on promoter function (Genuario et al., 1993), which could explain the multiple

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 19, 2024

Molecular Pharmacology Fast Forward. Published on September 21, 2004 as DOI: 10.1124/mol.104.003350
This article has not been copyedited and formatted. The final version may differ from this version.

bands observed at position A. The proteins of complex C could not be identified using antibody supershift EMSA. A probe with the mutation in EBS1, resembling the *SULT1A3* sequence displayed similar nuclear extract binding pattern to the *SULT1A1* wild type probe, and a supershift with the GABP α and β antibodies. No binding or supershifts were observed for the probe containing mutations in all three EBSs. The ability of these Ets factors to bind the *SULT1A1* -102/-85 EBS probe was further highlighted when recombinant, *in vitro* expressed Ets proteins Elf1, Elk1 and the GABP heterodimer were shown to form DNA:protein complexes in EMSA (Figure 6b). Ets1, Ets2, Tel and the empty expression vector did not form visible complexes with the *SULT1A1* probe, which suggests that the EBS site of the *SULT1A1* promoter shows selectivity in the binding of Ets factors. A mutation in EBS3 of the *SULT1A1* probe did not change the binding affinity for Elf1 or Elk1, but compromised binding of the GABP heterodimer. Binding of all factors was drastically reduced with the mutation in EBS1, which represents the same sequence as wild type *SULT1A3* (Figure 6b). Binding was totally abolished for all factors when the three EBS sites were mutated, suggesting that the presence of the triplicate repeat of EBS is required for optimal binding of a broader variety of Ets factors.

Recombinant Ets factors influence *SULT1A* promoter activity in S2 cells. To assess the ability of Ets factors to induce the *SULT1A1* promoter, we utilized the *Drosophila melanogastor* cell line S2, which lacks a large variety of mammalian transcription factors. Transfection of Ets factors in HepG2 cells suggested an effect of these on *SULT1A1* promoter activity, however the changes in activity were moderate, most likely due to the action of endogenous Ets factors on the promoter. In contrast, the

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 19, 2024

Molecular Pharmacology Fast Forward. Published on September 21, 2004 as DOI: 10.1124/mol.104.003350
This article has not been copyedited and formatted. The final version may differ from this version.

SULT1A1 promoter had no basal activity in the S2 cells, with luciferase values close to those observed for the empty pGL3Basic vector, suggesting that no endogenous transcription factors were affecting the promoter in these cells (Figure 7a). When the Ets transcription factors were co-transfected, an increase in *SULT1A1* promoter activity was observed with the GABP heterodimer and Elf1, but not with other Ets factors. This induction was dependent on increasing amounts of Ets factor transfected and 5μg of either Elf1 or GABPα/β resulted in a 4-fold induction of promoter activity. The data show that transcriptional activation by GABP proteins could only be conferred in the presence of both heterodimeric partners. Even though we showed recombinant Elk1 binding, it appears that under the conditions in S2 cells, Elk1 is unable to transactivate the *SULT1A1* promoter. Tel, a known Ets repressor, which showed no obvious binding on EMSA, and no inducibility of the *SULT1A1* promoter was able to repress the promoter activity induced by the GABP heterodimer (Figure 7a; Lopez et al., 1999). The inducibility of GABP and Elf1 on *SULT1A1* promoter activity was compromised when mutations were made in the individual EBS motifs and totally abolished in the triplicate mutant (Figure 7b). Interestingly, inducibility of the *SULT1A3* promoter could be observed with GABP and Elf1, although the binding of the recombinantly expressed proteins was compromised in EMSA with the EBS1 mutant, which corresponds to the *SULT1A3* sequence (Figure 6b). This suggests that the reason for the difference between *SULT1A1* and *SULT1A3* promoter activities observed in the hepatocarcinoma cell lines is more complex than the difference in binding and consequent action of Ets transcription factors at EBS1.

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 19, 2024

Molecular Pharmacology Fast Forward. Published on September 21, 2004 as DOI: 10.1124/mol.104.003350
This article has not been copyedited and formatted. The final version may differ from this version.

Sp1 acts in synergy with GABP to induce the *SULT1A1* promoter. The role of the two Sp1 motifs flanking the EBS region in the *SULT1A1* promoter were assessed using site directed mutagenesis. Mutations in either site reduced *SULT1A1* -112/+65 promoter activity by 30% in HepG2 cells (Figure 8a). A mutation in both sites resulted in a 70% reduction in activity. When the recombinant Sp1 transcription factor was co-transfected with the *SULT1A1* promoter and its Sp1 site mutants into S2 cells, a similar pattern of activity was seen as in HepG2 cells, suggesting that the endogenous levels of Sp1 play an important role in driving the *SULT1A1* promoter (Figure 8b). Sp1 had strong effects on the wild type promoter, inducing its activity 17-fold.

Previous studies have shown that Sp1 and GABP can interact to co-activate transcription of genes (Galvagni et al., 2001; Jiang et al., 2002). When co-transfecting Sp1 and GABP into S2 cells we noted an overall 45-fold induction of the *SULT1A1* promoter (Figure 9). Alone GABP and Sp1 were able to induce the promoter 4- and 17-fold respectively, indicating that this high induction represents a synergy between the two factors, with Sp1 inducing the GABP-mediated activation approximately 10-fold. Although on its own Ets1 appeared not to induce the *SULT1A1* promoter, an enhanced effect of the Sp1 induction was observed when co-transfected with Ets1. Elf1 failed to show a synergistic effect; with co-transfection of both Elf1 and Sp1 resulting in a 13-fold additive induction.

Synergistic interaction between Sp1 and GABP is compromised on the *SULT1A3* promoter due to a lack of EBS1. To asses the role of the Ets and Sp1 binding sites in determining the synergy between Sp1 and GABP, the ability of these two transcription factors to induce the promoter activity of the *SULT1A1* mutant constructs was assessed

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 19, 2024

Molecular Pharmacology Fast Forward. Published on September 21, 2004 as DOI: 10.1124/mol.104.003350
This article has not been copyedited and formatted. The final version may differ from this version.

in S2 cells. A mutation in the first Sp1 site (Sp1A) reduced the ability of Sp1 to induce the promoter by 50%, which in turn caused a decrease in the synergistic induction produced with GABP from 45- to 20-fold. Synergy was totally abolished after mutating the second Sp1 site (Sp1B) indicating it's importance in this transcriptional mechanism (Figure 10a).

Further, it was found that EBS1 and EBS3 are needed for the synergistic effect between GABP and Sp1 to occur. Mutations in either site abolished synergy between the two transcription factors, suggesting that it is necessary for Ets factors to have a specific conformational binding to the promoter for the interaction with Sp1 to occur, that is dependent on the presence of all three EBSs (Figure 10b). Since EBS1 appears to be necessary for this synergy, we tested the ability of GABP and Sp1 to act in synergy in the induction of the *SULT1A3* promoter, which lacks this site. No synergy in induction could be observed with this promoter and it appears that the activity of the *SULT1A3* promoter is solely driven by Sp1, and perhaps an additive effect of Ets factors binding at EBS2 and 3.

Discussion:

Previous studies have shown that rat and bovine SULT1A1 levels can be modulated by polycyclic aromatic hydrocarbon receptor agonists and nuclear receptor activators, such as dexamethasone, phenobarbital (Runge-Morris, 1998). Additionally, levels of other Phase I and II metabolic enzymes including the CYP family, UGT and the hydroxysteroid sulfotransferases (SULT2), are influenced by nuclear receptor activators (Runge-Morris, 1998; Sugatani et al., 2001; Pascussi et al., 2003). Unlike these enzymes, human SULT1A1 expression does not appear to be induced by any foreign

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 19, 2024

Molecular Pharmacology Fast Forward. Published on September 21, 2004 as DOI: 10.1124/mol.104.003350
This article has not been copyedited and formatted. The final version may differ from this version.

chemical stimuli thus far explored, but is constitutively expressed at high levels in hepatic and many extrahepatic tissues. In this study the negligible effects of the glucocorticoid receptor agonist on human SULT1A1 levels in primary human hepatocytes were reconfirmed, which is in contrast to the dexamethasone inducible expression of the rat SULT1A1 enzyme (Duanmu et al., 2002; Duanmu et al., 2001). In addition, all other nuclear receptor ligands failed to change human SULT1A1 and SULT1A3 mRNA levels in primary human hepatocytes. It appears that the human SULT1A1 enzyme exhibits a regulation profile that is unique from its rodent homologues, with high expression, wide tissue distribution and a lack of gender specific regulation. The high levels of human SULT1A1 reported in the liver and many extrahepatic tissues is suggestive of a more ubiquitous pattern of regulation. This study aimed to investigate the molecular mechanisms of *SULT1A1* gene regulation at the promoter level.

The isolation of different 5'UTRs of SULT1A cDNA species, suggested the use of alternate transcriptional start sites on the genes (Wilborn et al., 1993; Zhu et al., 1993a; Zhu et al., 1993b; Bernier et al., 1994a; Wood et al., 1994; Aksoy and Weinshilboum, 1995; Raftogianis et al., 1996). In this study the primary transcript from 5'RACE and RT-PCR of HepG2 cells contained the previously identified distal 5'UTR of SULT1A1 (Zhu et al., 1993b). When assessing the promoter activities of sequences flanking all 5'UTRs reported, this distal 5'UTR B was shown to house the most active and primary promoter in the liver like environment of hepatocarcinoma cell lines and primary human hepatocytes. This promoter lacks a canonical TATA box element but contains G/C rich regions near its transcriptional start site. High activity of the distal promoter was also seen in other cell lines, other than those derived from a liver origin, such as MCF-7 and

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 19, 2024

Molecular Pharmacology Fast Forward. Published on September 21, 2004 as DOI: 10.1124/mol.104.003350
This article has not been copyedited and formatted. The final version may differ from this version.

Caco2 (results not shown), suggesting a ubiquitous mechanism of transcriptional control of the *SULT1A1* gene in a variety of tissues.

Although the SULT1A1 and SULT1A3 enzymes share >93% amino acid homology, their tissue specific expression varies markedly, best demonstrated by the high abundance of SULT1A1 in the adult liver compared to very low SULT1A3 levels (Figure 1f and g; Windmill et al., 1998; Richard et al., 2001). The human *SULT1A1* and *SULT1A3* genes share >70% sequence identity, with highest diversity being present in the promoter and intron regions. A cDNA species containing a 5'UTR homologous to the distal 5'UTR identified for SULT1A1 was also found for SULT1A3 cDNAs isolated from a liver (Aksoy and Weinshilboum, 1995) and placental (Bernier et al., 1994b) library. Other 5'UTRs further upstream of this have also been reported (Bernier et al., 1994b; Aksoy and Weinshilboum, 1995; Zhu et al., 1993a). Bernier *et al.* (1994a) reported that the *SULT1A3* sequence flanking the 5'UTR homologous to the *SULT1A1* distal 5'UTR B has higher promoter activity than that flanking the other *SULT1A3* 5'UTR, which was confirmed in this study. This suggests that both genes use a homologous region of their gene sequence as promoters. When the activities of the minimal homologous promoters were compared, the *SULT1A1* -112/+65 promoter was shown to have 3-fold higher activity than the *SULT1A3* -125/+43 promoter construct, although sharing >77% sequence identity in this region. This difference appeared to be due to a lack of one EBS core sequence motif, GGAA. The importance of this binding site as a crucial element in the regulation of the *SULT1A1* promoter was highlighted when the activities of the two *SULT1A* promoters could effectively be reversed by exchanging two bases in EBS1. Further, it was shown that the adjacent EBS motifs were also important for *SULT1A1* promoter activity and determining optimal binding of Ets factors to this site. An EBS

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 19, 2024

Molecular Pharmacology Fast Forward. Published on September 21, 2004 as DOI: 10.1124/mol.104.003350
This article has not been copyedited and formatted. The final version may differ from this version.

motif is generally made up of the purine rich GGAA/T core, which is the binding site for the 85 amino acid ETS domain of Ets transcription factors (Graves and Petersen, 1998). More than 30 human members of this transcription factor family have been isolated, which have been shown to control a vast variety of genes including viral genes, antigen receptors, transcription factors, cytokines, growth factors, myeloid and lymphoid specific genes and genes involved in angiogenesis (Oikawa and Yamada, 2003). Due to the wide expression profile of SULT1A1, ubiquitously expressed Ets transcription factors were targeted as potential regulators of *SULT1A1* gene regulation. It was found that ubiquitously expressed Ets factors, GABPα, β and Elf1, from hepatocarcinoma cell lines were able to bind the *SULT1A1* EBS probe and that recombinant forms of these factors could induce the *SULT1A1* promoter in S2 cells.

Ets factors have been shown to act in synergy with a variety of transcription factors including Sp1 (Oikawa and Yamada, 2003). Mutations of the Sp1 consensus binding sites flanking the *SULT1A1* EBS were shown to influence the promoter's activity and Sp1 was shown to significantly enhance the GABP induced activity of the SULT1A1 promoter in S2 cells. This synergistic effect between GABP and Sp1 has been observed in other promoters, such as those of the human *utrophin* and *heparanase-1* genes, which are also TATA-less promoters (Galvagni et al., 2001; Jiang et al., 2002). It has been shown that Sp1 and Sp3 can directly interact with GABPα, but not GABPβ (Galvagni et al., 2001). Sp3 was also able to act in synergy with GABP to induce the *SULT1A1* promoter, although less effectively than Sp1 (results not shown). It was recently shown that Sp1 also regulates the promoters of human *PAPS synthase 1* and *2*, encoding the enzyme responsible for the synthesis of the sulfonate donor PAPS

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 19, 2024

Molecular Pharmacology Fast Forward. Published on September 21, 2004 as DOI: 10.1124/mol.104.003350
This article has not been copyedited and formatted. The final version may differ from this version.

(Shimizu et al., 2001; Shimizu et al., 2002). Sp1 is an important transcription factor that is necessary for development and cell cycle regulation. It also appears to be required for the regulation of the enzymes involved in sulfonation.

Interestingly, no synergy between GABP and Sp1 could be observed in the induction of the *SULT1A3* promoter, which lacks EBS1. Although individually, Ets factors and Sp1 were able to activate this promoter, the presence of the three EBS repeats appears to be necessary for correct binding of Ets factors to enable interaction with Sp1. GABP was able to synergistically enhance the Sp1 induced activity of the *SULT1A1* promoter 3-fold, which can be correlated to the same difference in activity observed between wild type *SULT1A1* and *SULT1A3* promoters in the hepatocarcinaoma cell lines. These data provide an insight into the differential regulation between the *SULT1A1* and *SULT1A3* genes in the adult liver. mRNA levels of SULT1A1 appear to be approximately 3-4 fold higher than those of SULT1A3 in primary human hepatocytes, which correlates with the difference in promoter activities observed. SULT1A3 protein is generally not readily detectable in the adult liver and was not seen in hepatocyte cytosol, unlike SULT1A1. This suggests that post-transcriptional modifications or protein stability differences between SULT1A1 and SULT1A3 may also contribute to the ultimate expression level of SULT1A3 in the adult liver. The abundant expression pattern of SULT1A1 suggests that this carcinogen-converting enzyme plays an important role in the detoxification and metabolic activation of xenobiotics entering the body through tissues such as skin, gut and liver (Windmill et al., 1998; Dooley et al., 2000). The role of ubiquitously expressed transcription factors in the regulation of *SULT1A1* may ensure constant expression of this enzyme at portals of entry for these compounds, to facilitate their rapid metabolism and elimination from the body.

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 19, 2024

Molecular Pharmacology Fast Forward. Published on September 21, 2004 as DOI: 10.1124/mol.104.003350
This article has not been copyedited and formatted. The final version may differ from this version.

The third gene of the SULT1A subfamily, *SULT1A2*, was shown to have a highly active promoter flanking its distal 5'UTR, which shares >95% sequence identity with the minimal *SULT1A1* promoter described in this study. This promoter contains the same EBS and Sp1 binding sites, suggesting that it shares a common mechanism of regulation with *SULT1A1*.

In conclusion, this study represents the first report elucidating the mechanisms of regulation of the human *SULT1A* sulfotransferase genes. The activity of the *SULT1A1* promoter appears to be dependent on a triplicate repeat of the ETS transcription factor binding site (EBS) core sequence GGAA. The ubiquitously expressed Ets transcription factors Elf and the GABP heterodimer are able to bind and induce transcriptional activation of the *SULT1A1* gene, of which the activation by GABP was synergistically enhanced by the presence of Sp1. Moreover, comparison to the related *SULT1A3* sequence, which has a two basepair mutation in one EBS core sequence revealed that the lack of this site abolished the synergy observed between GABP and Sp1.

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 19, 2024

Molecular Pharmacology Fast Forward. Published on September 21, 2004 as DOI: 10.1124/mol.104.003350
This article has not been copyedited and formatted. The final version may differ from this version.

Acknowledgements

Helpful discussions with Dr Tatsuya Sueyoshi, Dr Nancy Liyou and Dr Jean-Marc Pascussi are gratefully acknowledged.

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 19, 2024

Molecular Pharmacology Fast Forward. Published on September 21, 2004 as DOI: 10.1124/mol.104.003350
This article has not been copyedited and formatted. The final version may differ from this version.

References

Aksoy IA and Weinshilboum RM (1995) Human thermolabile phenol sulfotransferase gene (STM) molecular cloning and structural characterization. *Biochem Biophys Res Commun* **208:**786-795.

Bernier F, Leblanc G, Labrie F and Luu The V (1994a) Structure of human estrogen and aryl sulfotransferase gene. Two mRNA species issued from a single gene. *J Biol Chem* **269:**28200-28205.

Bernier F, Solache IL, Labrie F and Luu-The V (1994b) Cloning and expression of cDNA encoding human placental estrogen sulfotransferase. *Mol Cell Endocrinol* **99:**R11-R15.

Bernier F, Soucy P and Luu-The V (1996) Human phenol sulfotransferase gene contains two alternative promoters: Structure and expression of the gene. *DNA Cell Biol* **15:**367-375.

Brix LA, Barnett A, Duggleby RG and McManus ME (1999) Analysis of the catalytic specificity of human sulfotransferases SULT1A1 and SULT1A3: Site-directed mutagenesis and kinetic studies. *Biochemistry* **38:**10474-10479.

Butler PR, Anderson RJ and Venton DL (1983) Human platelet phenol sulfotransferase: partial purification and detection of two forms of the enzyme. *J Neurochem* **41:**630-639.

Dignam JD, Lebovitz RM and Roeder RG (1983) Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. *Nucleic Acids Res* **11:**1475-1489.

Dooley TP, Mitchison HM, Munroe PB, Probst P, Neal M, Siciliano MJ, Deng Z, Doggett NA, Callen DF, Gardiner RM and al e (1994) Mapping of two phenol

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 19, 2024

Molecular Pharmacology Fast Forward. Published on September 21, 2004 as DOI: 10.1124/mol.104.003350
This article has not been copyedited and formatted. The final version may differ from this version.

sulphotransferase genes, STP and STM, to 16p: candidate genes for Batten disease. *Biochem Biophys Res Commun* **205:**482-489.

Dooley TP and Huang Z (1996) Genomic organization and DNA sequences of two human phenol sulfotransferase genes (*STP1* and *STP2*) on the short arm of chromosome 16. *Biochem Biophys Res Commun* **228:**134-140.

Dooley TP, Haldeman-Cahill R, Joiner J and Wilborn TW (2000) Expression profiling of human sulfotransferase and sulfatase gene superfamilies in epithelial tissues and cultured cells. *Biochem Biophys Res Commun* **277:**236-245.

Duanmu Z, Kocarek TA and Runge-Morris M (2001) Transcriptional regulation of rat hepatic aryl sulfotransferase (SULT1A1) gene expression by glucocorticoids. *Drug Metab Dispos* **29:**1130-1135.

Duanmu Z, Locke D, Smigelski J, Wu W, Dahn MS, Falany CN, Kocarek TA and Runge-Morris M (2002) Effects of dexamethasone on aryl (SULT1A1)- and hydroxysteroid (SULT2A1)-sulfotransferase gene expression in primary cultured human hepatocytes. *Drug Metab Dispos* **30:**997-1004.

El-Sankary W, Plant NJ, Gibson GG and Moore DJ (2000) Regulation of the CYP3A4 gene by hydrocortisone and xenobiotics: role of the glucocorticoid and pregnane X receptors. *Drug Metab Dispos* **28:**493-496.

Falany CN (1997) Enzymology of human cytosolic sulfotransferases. *Faseb J* **11:**206-216.

Galvagni F, Capo S and Oliviero S (2001) Sp1 and Sp3 physically interact and co-operate with GABP for the activation of the utrophin promoter. *J Mol Biol* **306:**985-996.

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 19, 2024

Molecular Pharmacology Fast Forward. Published on September 21, 2004 as DOI: 10.1124/mol.104.003350
This article has not been copyedited and formatted. The final version may differ from this version.

Genuario RR, Kelley DE and Perry RP (1993) Comparative utilization of transcription factor GABP by the promoters of ribosomal protein genes rpL30 and rpL32. *Gene Expr* **3:**279-288.

Graves BJ and Petersen JM (1998) Specificity within the ets family of transcription factors. *Adv Cancer Res* **75:**1-55.

Jiang P, Kumar A, Parrillo JE, Dempsey LA, Platt JL, Prinz RA and Xu X (2002) Cloning and characterization of the human heparanase-1 (HPR1) gene promoter: role of GA-binding protein and Sp1 in regulating HPR1 basal promoter activity. *J Biol Chem* **277:**8989-8998.

LaMarco K, Thompson CC, Byers BP, Walton EM and McKnight SL (1991) Identification of Ets- and notch-related subunits in GA binding protein. *Science* **253:**789-792.

Lopez RG, Carron C, Oury C, Gardellin P, Bernard O and Ghysdael J (1999) TEL is a sequence-specific transcriptional repressor. *J Biol Chem* **274:**30132-30138.

Maglich JM, Parks DJ, Moore LB, Collins JL, Goodwin B, Billin AN, Stoltz CA, Kliewer SA, Lambert MH, Willson TM and Moore JT (2003) Identification of a novel human constitutive androstane receptor (CAR) agonist and its use in the identification of CAR target genes. *J Biol Chem* **278:**17277-17283.

Oikawa T and Yamada T (2003) Molecular biology of the Ets family of transcription factors. *Gene* **303:**11-34.

Ozawa S, Nagata K, Shimada M, Ueda M, Tsuzuki T, Yamazoe Y and Kato R (1995) Primary structures and properties of two related forms of aryl sulfotransferases in human liver. *Pharmacogenetics* **5 Spec No:**S135-140.

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 19, 2024

Molecular Pharmacology Fast Forward. Published on September 21, 2004 as DOI: 10.1124/mol.104.003350
This article has not been copyedited and formatted. The final version may differ from this version.

Pascussi JM, Gerbal-Chaloin S, Drocourt L, Maurel P and Vilarem MJ (2003) The expression of CYP2B6, CYP2C9 and CYP3A4 genes: a tangle of networks of nuclear and steroid receptors. *Biochim Biophys Acta* **1619:**243-253.

Raftogianis RB, Her C and Weinshilboum M (1996) Human phenol sulfotransferase pharmacogenetics: *STP1** gene cloning and structural characterization. *Pharmacogenetics* **6:**473-487.

Richard K, Hume R, Kaptein E, Stanley EL, Visser TJ and Coughtrie MW (2001) Sulfation of thyroid hormone and dopamine during human development: ontogeny of phenol sulfotransferases and arylsulfatase in liver, lung, and brain. *J Clin Endocrinol Metab* **86:**2734-2742.

Rubin GL, Harrold AJ, Mills JA, Falany CN and Coughtrie MW (1999) Regulation of sulphotransferase expression in the endometrium during the menstrual cycle, by oral contraceptives and during early pregnancy. *Mol Hum Reprod* **5:**995-1002.

Runge-Morris M (1998) Regulation of sulfotransferase gene expression by glucocorticoid hormones and xenobiotics in primary rat hepatocyte culture. *Chem Biol Interact* **109:**315-327.

Shimizu C, Fuda H, Lee YC and Strott CA (2001) Transcriptional regulation of human 3'-phosphoadenosine 5'- phosphosulfate synthase 1. *Biochem Biophys Res Commun* **284:**763-770.

Shimizu C, Fuda H, Lee YC and Strott CA (2002) Transcriptional regulation of human 3'-phosphoadenosine 5'- phosphosulphate synthase 2. *Biochem J* **363:**263-271.

Stanley EL, Hume R, Visser TJ and Coughtrie MW (2001) Differential expression of sulfotransferase enzymes involved in thyroid hormone metabolism during human placental development. *J Clin Endocrinol Metab* **86:**5944-5955.

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 19, 2024

Molecular Pharmacology Fast Forward. Published on September 21, 2004 as DOI: 10.1124/mol.104.003350
This article has not been copyedited and formatted. The final version may differ from this version.

Sugatani J, Kojima H, Ueda A, Kakizaki S, Yoshinari K, Gong QH, Owens IS, Negishi M and Sueyoshi T (2001) The phenobarbital response enhancer module in the human bilirubin UDP-glucuronosyltransferase UGT1A1 gene and regulation by the nuclear receptor CAR. *Hepatology* **33:**1232-1238.

Wang H, Faucette SR, Gilbert D, Jolley SL, Sueyoshi T, Negishi M and LeCluyse EL (2003) Glucocorticoid receptor enhancement of pregnane X receptor-mediated CYP2B6 regulation in primary human hepatocytes. *Drug Metab Dispos* **31:**620-630.

Wilborn TW, Comer KA, Dooley TP, Reardon IM, Heinrikson RL and Falany CN (1993) Sequence analysis and expression of the cDNA for the phenol-sulfating form of human liver phenol sulfotransferase. *Mol Pharmacol* **43:**70-77.

Windmill KF, Christiansen A, Teusner JT, Bhasker CR, Birkett DJ, Zhu X and McManus ME (1998) Localisation of aryl sulfotransferase expression in human tissues using hybridisation histochemistry and immunohistochemistry. *Chem Biol Interact* **109:**341-346.

Wood TC, Aksoy IA, Aksoy S and Weinshilboum RM (1994) Human liver thermolabile phenol sulfotransferase: cDNA cloning, expression and characterization. *Biochem Biophys Res Commun* **198:**1119-1127.

Wu W, Kocarek TA and Runge-Morris M (2001) Sex-dependent regulation by dexamethasone of murine hydroxysteroid sulfotransferase gene expression. *Toxicol Lett* **119:**235-246.

Yokomori N, Kobayashi R, Moore R, Sueyoshi T and Negishi M (1995) A DNA methylation site in the male-specific P450 (Cyp 2d-9) promoter and binding of the heteromeric transcription factor GABP. *Mol Cell Biol* **15:**5355-5362.

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 19, 2024

Molecular Pharmacology Fast Forward. Published on September 21, 2004 as DOI: 10.1124/mol.104.003350
This article has not been copyedited and formatted. The final version may differ from this version.

Zhu X, Veronese ME, Bernard CC, Sansom LN and McManus ME (1993a) Identification of two human brain aryl sulfotransferase cDNAs. *Biochem Biophys Res Commun* **195:**120-127.

Zhu X, Veronese ME, Sansom LN and McManus ME (1993b) Molecular characterisation of a human aryl sulfotransferase cDNA. *Biochem Biophys Res Commun* **192:**671-676.

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 19, 2024

Molecular Pharmacology Fast Forward. Published on September 21, 2004 as DOI: 10.1124/mol.104.003350
This article has not been copyedited and formatted. The final version may differ from this version.

Footnotes

This work was supported by the National Health and Medical Research Council of Australia (NH and MEM) and the National Institutes of Health, USA (HW, ELL and MN).

Address correspondence to: Dr. Michael E. McManus, Executive Dean, Faculty of Biological & Chemical Sciences, Bld 69, University of Queensland, Brisbane Qld 4072, Australia, Tel.: 61-7-3365-1609, Fax: 61-7-3365-1613, E-mail address: m.mcmanus@uq.edu.au

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 19, 2024

Molecular Pharmacology Fast Forward. Published on September 21, 2004 as DOI: 10.1124/mol.104.003350
This article has not been copyedited and formatted. The final version may differ from this version.

Figure Legends

Figure 1 (a-e) Real-time RT-PCR of primary human hepatocyte RNA after treatment with nuclear receptor activators. Data represent the results obtained from primary hepatocytes of one liver donor, isolated as stated in Methods. Hepatocytes were treated with 1mM phenobarbital (PB), 1μM Citco, 1μM dexamethasone (Dex), 10μM rifampicin (Rif), 5μM 3-methylcolanthrene (3-MC) or vehicle DMSO and RNA was isolated and reverse transcribed 18 hours post-treatment. Real-time PCR was carried out as stated in Materials and Methods and results represent the fold induction in SULT1A1 **(a)**, SULT1A3 **(b)**, CYP2B6 **(c)**, CYP3A4 **(d)** and UGT1A1 **(e)** mRNA levels after treatment compared to the DMSO control (n=2). **(f) SULT1A1 and SULT1A3 mRNA levels in primary human hepatocytes.** RNA was isolated from untreated primary human hepatocytes and reverse transcribed as stated in Methods. RT-PCR was carried out with SULT1A1 and SULT1A3 specific primers. **(g) Immunoblot of primary human hepatocyte cytosol with anti-human SULT1A antibody.** Human primany hepatocyte cytosol (75μg) and recombinant, bacterially expressed SULT1A1 and SULT1A3 proteins were electrophoresed and immunoblotted as described in Materials and Methods.

Figure 2 (a) Schematic of the 5' region of the human *SULT1A1* gene. Open boxes represent the location of the alternate 5'UTRs of SULT1A1 cDNA species identified in the literature and closed boxes the first and second coding exons of *SULT1A1*. The transcriptional start site identified by 5'RACE is labeled as +1. Promoter constructs are represented by black bars and these were cloned into the pGL3Basic Luciferase

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 19, 2024

Molecular Pharmacology Fast Forward. Published on September 21, 2004 as DOI: 10.1124/mol.104.003350
This article has not been copyedited and formatted. The final version may differ from this version.

reporter vector as stated in Materials and Methods. **(b) Promoter activities of sequences flanking the alternate 5'UTRs of *SULT1A1* in HepG2 cells.** All promoters were cloned into the pGL3Basic vector, transfected into HepG2 cells and lysed cells assayed for luciferase activity as stated in Methods. Results are corrected for *Renilla* luciferase activity of the pRLSV40 transfection standard and represent the mean ± SD of 3 transfections. Results are expressed as fold increases in luciferase activity relative to the empty pGL3Basic vector. Asterisks indicate significant differences to the activity of the empty pGL3Basic vector (Student's T-test, **p<0.01; ***p<0.001). **(c) *SULT1A1* promoter deletion construct activities in HepG2 cells.** Deletion constructs of the distal promoter were cloned into the pGL3Basic vector and transfected into HepG2 cells as described above. Results are expressed as a percentage of the *SULT1A1* -112/+65 construct promoter activity, with significant differences to this construct indicated by asterisks (*p<0.05; ***p<0.001). **(d) Promoter activities of *SULT1A1* promoter deletion constructs in HepG2, Hep3B and Primary Human Hepatocytes (Hepat).** The -68/+65 and -112/+65 *SULT1A1* promoter constructs were cloned into the pGL3Basic vector, transfected into cell lines and lysed cells assayed for luciferase activity as stated above. Results are expressed as a percentage of the *SULT1A1* -112/+65 construct promoter activity in each cell line, with significant differences to the activity of this construct indicated by asterisks (***p<0.001).

Figure 3 (a) Schematic of the 5' region of the human *SULT1A3* gene. Open boxes represent the location of the alternate 5'UTRs of SULT1A1 cDNA species identified in the literature and closed boxes the first and second coding exons of *SULT1A3*. The

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 19, 2024

Molecular Pharmacology Fast Forward. Published on September 21, 2004 as DOI: 10.1124/mol.104.003350
This article has not been copyedited and formatted. The final version may differ from this version.

5'UTR A transcriptional start site identified in the literature is labeled as +1 (Bernier et al., 1994a). Promoter constructs are represented by black bars and these were cloned into the pGL3Basic Luciferase reporter vector as stated in Methods. **(b) Promoter activities of sequences flanking the alternate 5'UTRs of *SULT1A3* in HepG2 cells.** All promoters were cloned into the pGL3Basic vector, transfected into HepG2 cells and lysed cells assayed for luciferase activity as stated in Methods. Results are corrected for *Renilla* luciferase activity of the pRLSV40 transfection standard and represent the mean ± SD of 3 transfections. Results are expressed as fold increases in luciferase activity relative to the empty pGL3Basic vector. Asterisks indicate significant difference to the activity of the empty pGL3Basic vector (***p<0.001).

Figure 4 (a) Comparison of promoter activities between *SULT1A1* and the homologous *SULT1A3* sequences. Constructs were cloned into pGL3Basic, transfected into HepG2 cells and lysed cells assayed for luciferase activity as stated in Methods. *SULT1A1* and *SULT1A3* promoter activities are represented by black and gray bars, respectively. Results are corrected for *Renilla* luciferase activity of the pRLSV40 transfection standard and expressed relative to the *SULT1A1* -112/+65 promoter activity (mean ± SD, n=3), with significant differences to this construct indicated by asterisks (*p<0.05; **p<0.01; ***p<0.001). **(b) Alignment of the *SULT1A1* -112/+3 and *SULT1A3* -125/-20 promoter sequences, and position of Sp1 and Ets binding sites (EBS).** Areas of sequence identity between *SULT1A1* and *SULT1A3* are represented by asterisks. EBS and Sp1 binding sites are schematically represented by circles and rectangles respectively. The locations and sequence modifications of the consensus site

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 19, 2024

Molecular Pharmacology Fast Forward. Published on September 21, 2004 as DOI: 10.1124/mol.104.003350
This article has not been copyedited and formatted. The final version may differ from this version.

mutations are shown below. The transcriptional start site is marked as +1 and the bases underlined display the probe sequence used for EMSA. **(c) Effects of nucleotide -112 to -68 exchange between the *SULT1A1* and *SULT1A3* promoters and mutation of EBS1.** The *SULT1A1* fragment from -112 to -68 was excised and replaced by the homologous *SULT1A3* sequence [1A1(alt1A3)]. Using site directed mutagenesis, EBS1 of *SULT1A1* was changed to the site found in *SULT1A3* (1A1EBS1m), and EBS1 introduced into *SULT1A3* (1A3EBS1m). Constructs were transfected into HepG2 cells as described above. *SULT1A1* and *SULT1A3* promoter activities are represented by black and gray bars respectively and expressed as a percentage of the *SULT1A1* -112/+65 promoter activity, with significant differences to this construct indicated by asterisks (**p<0.01; ***p<0.001).

Figure 5 (a) Effects of EBS motif mutations on *SULT1A1* promoter activity. EBS consensus elements were disrupted in the *SULT1A1* -112/+65 promoter construct using site directed mutagenesis (Figure 4a). Constructs were transfected into HepG2 cells and lysed cells assayed for luciferase as indicated Methods. Luciferase activity was normalized against *Renilla* luciferase activity of the transfection control pRLSV40 and results are expressed as a percentage of the wild type *SULT1A1* -112/+65 construct (mean ± SD, n=3). Asterisks indicate significant difference to the activity of this construct (*p<0.05; **p<0.01; ***p<0.001). **(b) Binding of HepG2 and Hep3B nuclear extract to the *SULT1A1* EBS motifs.** EMSAs were carried out as described in Methods. The -102/-85 *SULT1A1* ^{32}P radiolabeled probe containing the EBS motifs was incubated with either 4 μg of HepG2 or Hep3B nuclear extract (NE). In competition (Comp) experiments

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 19, 2024

Molecular Pharmacology Fast Forward. Published on September 21, 2004 as DOI: 10.1124/mol.104.003350
This article has not been copyedited and formatted. The final version may differ from this version.

10x, 100x or 500x molar excess of unlabelled wild type probe or the probe containing mutations in all three EBS (EBS1,2,3m) was included. Specific DNA:protein complexes that are competed out by molar excess of cold competitor are labeled by letters (A-C). A non-specific complex is labeled n/s **(c) Binding of HepG2 nuclear extract to ^{32}P radiolabeled mutant EBS probes.** EMSAs were carried out as described above with radiolabeled mutant and wild type -102/-85 *SULT1A1* probes and 4μg of HepG2 nuclear extract.

Figure 6 (a) Ets transcription factor antibody supershift EMSA. EMSA was carried out as described in Materials and Methods. HepG2 nuclear extract (5μg) was incubated with 2μg polyclonal antibody against Ets2, Elf1, GABPα, GABPβ or normal rabbit IgG (Rb-IgG), and either the ^{32}P radiolabeled *SULT1A1* -102/-85 wild type probe (SULT1A1 wt) or the radiolabeled EBS mutant probes. **(b) Binding of recombinant Ets factors to the *SULT1A1* EBS probe.** Recombinant Ets proteins were *in vitro* transcribed/translated in rabbit reticulocytes as described in Methods. ^{32}P radiolabeled *SULT1A1* -102/-85 wild type probe was incubated with 2μl of reticulocyte expressed protein and 100x molar excess of unlabeled probe was included in competition (Comp) experiments. Reticulocyte lysate containing empty expression vector pCDNA3.1 was run as control and EMSA carried out as described in Methods.

Figure 7 (a) Ets Factors influence *SULT1A1* -112/+65 promoter activity in S2 cells. S2 cells were transfected as indicated in Methods with 1μg *SULT1A1* -112/+65 promoter in pGL3Basic and 1μg, 2.5μg or 5μg of each Ets transcription factors in pAC5.1 vector.

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 19, 2024

Molecular Pharmacology Fast Forward. Published on September 21, 2004 as DOI: 10.1124/mol.104.003350
This article has not been copyedited and formatted. The final version may differ from this version.

The last two bars represent 5μg of GABPα and β co-transfected with 2.5 and 5μg of Tel. Luciferase activity of lysed cells was normalized against total protein and data represent the mean ± SD of 3 transfections and is expressed relative to promoter activity co-transfected with empty pAC5.1 vector. Asterisks indicate significant differences to the activity of the promoter transfected with pAC5.1 sample (*p<0.05; **p<0.01; ***p<0.001). **(b) Effects of Ets factors on *SULT1A1* -112/+65 EBS mutant and *SULT1A3* promoter constructs.** S2 cells were transfected as indicated in Methods with 5μg of Ets factors and 1μg promoter constructs in pGL3Basic vector. Luciferase activity was assessed as stated above and is expressed relative to each promoter construct's activity co-transfected with empty pAC5.1 vector. Asterisks indicate significant differences to the activity of each promoter construct transfected with the control pAC5.1 sample (*p<0.05; **p<0.01; ***p<0.001).

Figure 8 (a) Influence of Sp1 site mutations on *SULT1A1* –112/+65 promoter activity in HepG2 cells. Sp1 site mutations were made using site directed mutagenesis (Figure 4a), transfected into HepG2 cells and lysed cells assayed for Luciferase activity as stated in Methods. Results are corrected for pRLSV40 internal *Renilla* luciferase standard and expressed relative to the activity of the *SULT1A1* -112/+65 construct (mean ± SD, n=3). Asterisks indicate significant differences to this construct (*p<0.05; **p<0.01). **(b) Influence of Sp1 on *SULT1A1* -112/+65 promoter and Sp1 site mutants in S2 cells.** S2 cells were transfected as indicated in the Methods with *SULT1A1* promoter wild type (wt) and Sp1 mutant constructs (Figure 4a) in pGL3Basic and 2μg of Sp1 transcription factor in pPac-UBX vector. Luciferase activity of lysed cells

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 19, 2024

Molecular Pharmacology Fast Forward. Published on September 21, 2004 as DOI: 10.1124/mol.104.003350
This article has not been copyedited and formatted. The final version may differ from this version.

was normalized against total protein and data represent the mean ± SD of 3 transfections. Luciferase activity was expressed relative to each promoter construct's activity co-transfected with empty pPac-UBX 5.1 vector. Asterisks indicate significant differences to the activity of the SULT1A1 -112/+65 wild type promoter activity co-transfected with Sp1 (**p<0.01).

Figure 9 Sp1 and Ets transcription Factors GABP and Ets1 act synergistically on the *SULT1A1* -112/+65 promoter. *SULT1A1* -112/+65 promoter in pGL3Basic (wt) or the empty pGL3Basic vector were co-transfected with 5µg Ets transcription factors in pAC5.1 vector and either 2µg Sp1 or empty pPac-UBX vector into S2 cells as indicated in Methods. Luciferase activity of lysed cells was normalized against total protein and data represent the mean ± SD of 3 transfections. Results are expressed as fold increases from the promoter activity of the *SULT1A1* -112/+65 construct co-transfected with empty Ets transcription vector pAC5.1 and empty Sp1 transcription vector pPac-UBX. Asterisks indicate significant differences to the activity of the SULT1A1 -112/+65 construct transfected with Sp1 and pAC5.1 (**p<0.01; ***p<0.001).

Figure 10 (a) Influence of Sp1 site mutants on GABP - Sp1 synergy. *SULT1A1* promoter constructs were transfected with either GABP or empty vector pAC5.1 (5µg) and Sp1 or empty vector pPac-UBX (2µg) as indicated in Methods. Luciferase activity of lysed cells was normalized against total protein and data represent the mean ± SD of 3 transfections, and is expressed as fold increase from the promoter activity of -112/+65 construct co-transfected with empty Ets transcription vector pAC5.1 and empty Sp1

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 19, 2024

Molecular Pharmacology Fast Forward. Published on September 21, 2004 as DOI: 10.1124/mol.104.003350
This article has not been copyedited and formatted. The final version may differ from this version.

transcription vector pPac-UBX. Asterisks indicate significant differences to the activity of each promoter construct transfected with Sp1 and the empty expression vector pAC5.1 (**p<0.01; ***p<0.001 **(b) The *SULT1A3* promoter cannot support GABP - Sp1 synergy as all EBS sites are required.** *SULT1A1* and *SULT1A3* promoter constructs were transfected with either GABP or empty vector pAC5.1 (5µg) and Sp1 or empty vector pPac-UBX (2µg). Luciferase Activity was assessed as above with results expressed expressed as fold increase from the promoter activity of -112/+65 construct co-transfected with empty Ets transcription vector pAC5.1 and empty Sp1 transcription vector pPac-UBX. Asterisks indicate significant differences to the activity of each promoter construct transfected with Sp1 and the empty Ets expression vector pAC5.1 (***p<0.001).

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 19, 2024

Figure 1


a
SULT1A1
Fold Induction
0
1
2
3
DMSO
PB
Citco
Dex
Rif
3-MC
b
SULT1A3
Fold Induction
0
1
2
3
DMSO
PB
Citco
Dex
Rif
3-MC
c
CYP2B6
Fold Induction
0
1
2
3
4
5
6
7
8
9
10
11
DMSO
PB
Citco
d
CYP3A4
Fold Induction
0
1
2
3
4
5
6
7
8
9
10
11
DMSO
Dex
Rif
e
UGT1A1
Fold Induction
0
1
2
3
4
5
6
7
8
9
10
11
DMSO
PB
Citco
Dex
Rif
3-MC
f
Size (bp)
SULT1A1
SULT1A3
200
100
g
MW (kDa)
Hepatocyte
SULT1A1
SULT1A3
36
Anti-hsaSULT1A

Figure 2


a
SULT1A1
-1212
+1
+65
B
A
I
II
Exon I (1371bp)
5'UTR A (657bp)
5'UTR B (1282bp)
Luc


b
Corrected Luciferase Activity
180
160
140
120
100
80
60
40
20
0
**
***
pGL3Basic
Exon I
5'UTR A
5'UTR B


c
Corrected Luciferase Activity
(% of SULT1A1 -112/+65)
120
100
80
60
40
20
0
*
*
*
***
***
pGL3Basic
-2887/+65
-2325/+65
-1217/+65
-542/+65
-232/+65
-144/+65
-112/+65
-68/+65
-1/+65


d
Corrected Luciferase Activity
(% of SULT1A1 -112/+65)
140
120
100
80
60
40
20
0
HepG2
Hep3B
Hepat.
***
***
***
-112/+65
-68/+65

Figure 3


a
SULT1A3
-1074
+1 +43
C
B
A
I
II
Exon I (1607bp)
5'UTR A (1117bp)
5'UTR B (623bp)
5'UTR C (2564bp)
Luc
b
Corrected Luciferase Activity
22
20
18
16
14
12
10
8
6
4
2
0
***
pGL3Basic
Exon I
5'UTR A
5'UTR B
5'UTR C

Figure 4


a
Corrected Luciferase Activity (% of SULT1A1 -112/+65)
120
100
80
60
40
20
0
pGL3Basic
-1217/+65
-542/+65
-232/+65
-112/+65
-68/+65
-1/+65
-1074/+65
-560/+43
-265/+43
-125/+43
-89/+43
-22/+43
SULT1A1
SULT1A3


b
Sp1
A
3
EBS
2
1
Sp1
B
SULT1A1 -112 CAACCCCACCCCTTCCTTCCGGAAGCAAATCTAAGTCCAGCCCCGGCTCCAGATCCC -56
SULT1A3 -125 CAACCCCACCCCTTCCTTCCTGGAGTT--------CCCAGCCCTGACTTTAGATCCC -77
1A1EBS1m .....T.G.....
1A3EBS1m .....G.A.....
1A1EBS2m .....C.A.....
1A1EBS3m .....C.A.....
1A1Sp1Am .....TT.T.....
1A1Sp1Bm .....TTT.....
SULT1A1 -55 TCCCACAGTGGACCTAGGAAACCCTCAGCTCAGAGAACAACCCTGCATTCCCCACAC +3
SULT1A3 -76 TCCCACACTGGACCTTCAAAACCCTCAGGGCAGAGAGCAGCCCTACACTCCCTACAC -20


c
Corrected Luciferase Activity (% of SULT1A1 wt)
140
120
100
80
60
40
20
0
wt
alt1A3
EBS1m
wt
EBS1m
1A1
1A3

Figure 5


a
Corrected Luciferase Activity (% of SULT1A1 wt)
120
100
80
60
40
20
0
**
**
*
***
SULT1A1wt
EBS1m
EBS2m
EBS3m
EBS1,2,3m
b
32P-102/-85
NE:
HepG2
Hep3B
Comp.:
wt
mut
wt
mut
A
B
n/s
C
free probe
c
32P Probe
-102/-85
EBS1m
EBS2m
EBS3m
EBS2,3m
EBS1,2,3m

Figure 6


a
32P Probe:
-102/-85 wt
EBS3mut
EBS1,2,3mut
EBS1mut
Antibody:
Rb-IgG
Ets2
Elf1
GABPα
GABPβ
A
B
n/s
C
b
32P Probe:
-102/-85 wt
EBS3mut
EBS1mut
EBS1.2.3mut
Ets protein:
Comp.:
pCDNA3.1
Ets1
Ets2
Elk
Elf1
TEL
GABPα&β

Figure 7


a
Fold Increase in Corrected Luciferase Activity
pAC5.1
Ets1
Ets2
Tel1
Elk1
Elf1
GABPα
GABP α&β
GABP +Tel1


b
Fold Increase in Corrected Luciferase Activity
pAC5.1
Elf1
GABP
pGL3 Basic
1A1 wt
1A1 EBS1m
1A1 EBS3m
1A1 EBS 1,2,3m
1A3 wt

Figure 8


a
Corrected Luciferase Activity
(% of SULT1A1 wt)
120
100
80
60
40
20
0
*
*
**
SULT1A1wt
Sp1Am
Sp1Bm
Sp1A,Bm


b
Fold Increase in
Corrected Luciferase Activity
20
15
10
5
0
pPac-UBX
Sp1
**
**
**
pGL3Basic
SULT1A1wt
Sp1Am
Sp1Bm
Sp1A,Bm

Figure 9


Fold Increase in Corrected Luciferase Activity
50
45
40
35
30
25
20
15
10
5
0
pPac-UBX
Sp1
**
*
***
pAC5.1
Ets1
Ets2
Tel1
Elk1
Elf1
GABP
pAC5.1
Ets1
Ets2
Tel1
Elk1
Elf1
GABP
SULT1A1 -112/+65 wt
pGL3Basic

Figure 10


a
b
Fold Increase in Corrected Luciferase Activity
50
45
40
35
30
25
20
15
10
5
0
***
**
pPac-UBX
Sp1
pAC5.1
GABP
1A1
wt
Sp1A
m
Sp1B
m
1A1
wt
1A1
EBS1m
1A1
EBS3m
1A3
wt